Logo image of KOD

KODIAK SCIENCES INC (KOD) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:KOD - US50015M1099 - Common Stock

28.32 USD
+0.26 (+0.93%)
Last: 1/13/2026, 4:30:02 PM
28.4 USD
+0.08 (+0.28%)
After Hours: 1/13/2026, 4:30:02 PM
Fundamental Rating

2

KOD gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 528 industry peers in the Biotechnology industry. KOD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. KOD does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year KOD has reported negative net income.
In the past year KOD has reported a negative cash flow from operations.
In the past 5 years KOD always reported negative net income.
KOD had a negative operating cash flow in each of the past 5 years.
KOD Yearly Net Income VS EBIT VS OCF VS FCFKOD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

The Return On Assets of KOD (-99.66%) is worse than 74.43% of its industry peers.
The Return On Equity of KOD (-917.34%) is worse than 78.98% of its industry peers.
Industry RankSector Rank
ROA -99.66%
ROE -917.34%
ROIC N/A
ROA(3y)-52.31%
ROA(5y)-39.78%
ROE(3y)-97.26%
ROE(5y)-69.5%
ROIC(3y)N/A
ROIC(5y)N/A
KOD Yearly ROA, ROE, ROICKOD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KOD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KOD Yearly Profit, Operating, Gross MarginsKOD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

KOD has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for KOD has been increased compared to 5 years ago.
There is no outstanding debt for KOD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KOD Yearly Shares OutstandingKOD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
KOD Yearly Total Debt VS Total AssetsKOD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

KOD has an Altman-Z score of -8.21. This is a bad value and indicates that KOD is not financially healthy and even has some risk of bankruptcy.
KOD has a worse Altman-Z score (-8.21) than 68.37% of its industry peers.
There is no outstanding debt for KOD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.21
ROIC/WACCN/A
WACCN/A
KOD Yearly LT Debt VS Equity VS FCFKOD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

KOD has a Current Ratio of 1.78. This is a normal value and indicates that KOD is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of KOD (1.78) is worse than 77.84% of its industry peers.
KOD has a Quick Ratio of 1.78. This is a normal value and indicates that KOD is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.78, KOD is doing worse than 76.52% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.78
Quick Ratio 1.78
KOD Yearly Current Assets VS Current LiabilitesKOD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for KOD have decreased strongly by -12.88% in the last year.
EPS 1Y (TTM)-12.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.1%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, KOD will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.89% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-27.2%
EPS Next 2Y-2.06%
EPS Next 3Y0.84%
EPS Next 5Y11.89%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KOD Yearly Revenue VS EstimatesKOD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
KOD Yearly EPS VS EstimatesKOD Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KOD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year KOD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KOD Price Earnings VS Forward Price EarningsKOD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KOD Per share dataKOD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.06%
EPS Next 3Y0.84%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KOD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

KODIAK SCIENCES INC

NASDAQ:KOD (1/13/2026, 4:30:02 PM)

After market: 28.4 +0.08 (+0.28%)

28.32

+0.26 (+0.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-25 2026-03-25/amc
Inst Owners76.6%
Inst Owner Change0.02%
Ins Owners4.78%
Ins Owner Change0%
Market Cap1.50B
Revenue(TTM)N/A
Net Income(TTM)-217.34M
Analysts75
Price Target22.59 (-20.23%)
Short Float %9.44%
Short Ratio5.05
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.6%
Min EPS beat(2)-11.61%
Max EPS beat(2)4.42%
EPS beat(4)2
Avg EPS beat(4)-5.48%
Min EPS beat(4)-20.72%
Max EPS beat(4)5.97%
EPS beat(8)5
Avg EPS beat(8)-4.03%
EPS beat(12)7
Avg EPS beat(12)-2.61%
EPS beat(16)9
Avg EPS beat(16)-3.73%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.03%
PT rev (3m)176.79%
EPS NQ rev (1m)2.08%
EPS NQ rev (3m)-5.94%
EPS NY rev (1m)0.57%
EPS NY rev (3m)-2.49%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 63.41
P/tB 63.41
EV/EBITDA N/A
EPS(TTM)-4.12
EYN/A
EPS(NY)-3.5
Fwd EYN/A
FCF(TTM)-2.4
FCFYN/A
OCF(TTM)-2.39
OCFYN/A
SpS0
BVpS0.45
TBVpS0.45
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -99.66%
ROE -917.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.31%
ROA(5y)-39.78%
ROE(3y)-97.26%
ROE(5y)-69.5%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.15%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.78
Quick Ratio 1.78
Altman-Z -8.21
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)491.62%
Cap/Depr(5y)1852.64%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.1%
EPS Next Y-27.2%
EPS Next 2Y-2.06%
EPS Next 3Y0.84%
EPS Next 5Y11.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-8.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.57%
EBIT Next 3Y-18.62%
EBIT Next 5YN/A
FCF growth 1Y35.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y28.29%
OCF growth 3YN/A
OCF growth 5YN/A

KODIAK SCIENCES INC / KOD FAQ

What is the ChartMill fundamental rating of KODIAK SCIENCES INC (KOD) stock?

ChartMill assigns a fundamental rating of 2 / 10 to KOD.


What is the valuation status of KODIAK SCIENCES INC (KOD) stock?

ChartMill assigns a valuation rating of 0 / 10 to KODIAK SCIENCES INC (KOD). This can be considered as Overvalued.


What is the profitability of KOD stock?

KODIAK SCIENCES INC (KOD) has a profitability rating of 0 / 10.


How financially healthy is KODIAK SCIENCES INC?

The financial health rating of KODIAK SCIENCES INC (KOD) is 5 / 10.